The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review
- PMID: 38598002
- DOI: 10.1007/s12094-024-03478-5
The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review
Abstract
Indeed, tumors are a significant health concern worldwide, and understanding the underlying mechanisms of tumor development is crucial for effective prevention and treatment. Epigenetics, which refers to changes in gene expression that are not caused by alterations in the DNA sequence itself, plays a critical role in the entire process of tumor development. It goes without saying that the effect of methylation on tumors is a significant aspect of epigenetics. Among the methylation modifications, DNA methylation is an important part, which plays a regulatory role in tumor-related genes. Ten-eleven translocation 2 (TET2) is a highly influential protein involved in the modification of DNA methylation. Its primary role is associated with the suppression of tumor development, making it a significant player in cancer research. However, TET2 is frequently mentioned in hematological diseases, its role in solid tumors has received little attention. Studying the changes of TET2 in solid tumors and the regulatory mechanism will facilitate its investigation as a clinical target for targeted therapy and may also provide directions for clinical treatment of malignant tumors.
Keywords: DNA methylation; Epigenetic; Solid tumors; TET2.
© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).
Similar articles
-
Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.Clin Epigenetics. 2019 Mar 27;11(1):54. doi: 10.1186/s13148-019-0651-z. Clin Epigenetics. 2019. PMID: 30917865 Free PMC article.
-
Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma.Oncotarget. 2017 Jan 3;8(1):315-328. doi: 10.18632/oncotarget.13324. Oncotarget. 2017. PMID: 27852070 Free PMC article.
-
TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis.DNA Cell Biol. 2018 Jun;37(6):517-523. doi: 10.1089/dna.2017.4118. Epub 2018 Apr 13. DNA Cell Biol. 2018. PMID: 29653065 Free PMC article. Review.
-
DNA methylcytosine dioxygenase ten-eleven translocation 2 enhances lipopolysaccharide-induced cytokine expression in human dental pulp cells by regulating MyD88 hydroxymethylation.Cell Tissue Res. 2018 Aug;373(2):477-485. doi: 10.1007/s00441-018-2826-x. Epub 2018 Apr 13. Cell Tissue Res. 2018. PMID: 29654353
-
TETology: Epigenetic Mastermind in Action.Appl Biochem Biotechnol. 2021 Jun;193(6):1701-1726. doi: 10.1007/s12010-021-03537-5. Epub 2021 Mar 10. Appl Biochem Biotechnol. 2021. PMID: 33694104 Review.
References
-
- Pan Y, Liu G, Zhou F, Su B, Li Y. DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 2018;18:1–14. https://doi.org/10.1007/s10238-017-0467-0 . - DOI - PubMed
-
- Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19:145. https://doi.org/10.1186/s12943-020-01258-7 . - DOI - PubMed - PMC
-
- Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer. 2020;6:580–92. https://doi.org/10.1016/j.trecan.2020.02.003 . - DOI - PubMed - PMC
-
- Meng H, Cao Y, Qin J, Song X, Zhang Q, Shi Y, et al. DNA methylation, its mediators and genome integrity. Int J Biol Sci. 2015;11:604–17. https://doi.org/10.7150/ijbs.11218 . - DOI - PubMed - PMC
-
- Dai X, Ren T, Zhang Y, Nan N. Methylation multiplicity and its clinical values in cancer. Expert Rev Mol Med. 2021;23:e2. https://doi.org/10.1017/erm.2021.4 . - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical